Tratament revoluționar pentru colesterolul "rău": o singură perfuzie ar putea avea efect ani întregi • Newsweek România

VERVE-102 is an experimental gene therapy that aims to provide a long-lasting reduction in LDL cholesterol with a single intravenous infusion. Initial results show sustained LDL reductions for up to a year, targeting the PCSK9 gene to alter cholesterol regulation. Unlike traditional statins, which require daily administration, VERVE-102 is designed for one-time use, potentially transforming cholesterol management. However, it remains in clinical trials, and long-term safety and efficacy need further investigation. Researchers emphasize caution in interpreting early results, as ongoing monitoring of patients is crucial to assess the therapy's lasting effects and any potential adverse outcomes.